Lexicon Pharmaceuticals
LXRX
144 hedge funds and large institutions have $2.01B invested in Lexicon Pharmaceuticals in 2016 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 57 increasing their positions, 41 reducing their positions, and 19 closing their positions.
273% more call options, than puts
Call options by funds: $18.4M | Put options by funds: $4.94M
39% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 41
32% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 19
26% more capital invested
Capital invested by funds: $1.59B → $2.01B (+$421M)
4% more funds holding
Funds holding: 138 → 144 (+6)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$11.9M |
| 2 |
CCI
Columbus Circle Investors
|
+$8.88M |
| 3 |
D.E. Shaw & Co
New York
|
+$7.56M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
+$5.97M |
| 5 |
KCM
Kingdon Capital Management
New York
|
+$5.07M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS AM
Chicago,
Illinois
|
-$28.6M |
| 2 |
BM
Bridger Management
New York
|
-$11.2M |
| 3 |
HW
Hancock Whitney
Gulfport,
Mississippi
|
-$9.53M |
| 4 |
FPC
Falcon Point Capital
San Francisco,
California
|
-$4.13M |
| 5 |
GAM
Gotham Asset Management
New York
|
-$3.98M |
LXRX Hedge Fund Activity: Q3 2016 in Review
144 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Lexicon Pharmaceuticals (LXRX) for Q3 2016, worth a combined $2.01B — up 26% from $1.59B a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new LXRX positions and 19 closed out — a net gain of 6 holders — while 57 added to existing stakes and 41 trimmed.
The largest buyer was Arrowstreet Capital, adding an estimated $11.9M. The largest seller was UBS AM, cutting an estimated $28.6M.
- 144 institutional investors held Lexicon Pharmaceuticals (LXRX) as of Q3 2016, up from 138 in Q2 2016.
- Funds reported $2.01B of Lexicon Pharmaceuticals stock for Q3 2016, up 26% quarter-over-quarter.
- 25 funds opened new Lexicon Pharmaceuticals positions in Q3 2016 and 19 closed out, a net change of +6 holders.
- The largest Lexicon Pharmaceuticals buyer in Q3 2016 was Arrowstreet Capital, an estimated $11.9M added.
- The largest Lexicon Pharmaceuticals seller in Q3 2016 was UBS AM, an estimated $28.6M sold.
Based on aggregated 13F filings for Q3 2016.